A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

  • End date
    Mar 1, 2022
  • participants needed
  • sponsor
    John Wayne Cancer Institute
Updated on 26 April 2021


The purpose of this study is to test the safety and tolerability of the research study drugs nivolumab, ipilimumab, lomustine, bevacizumab, and temozolomide when used following surgery and before standard therapy with radiation and temozolomide in patients with newly diagnosed high grade glioma.

Additional aims of the study are to:

  • Find out side effects (good and bad) of study drug combinations.
  • Evaluate any preliminary evidence of anticancer activity of study drug combinations .
  • Evaluate tumor characteristics by collecting brain tumor tissue samples.
  • Measure the amount of nivolumab and ipilimumab in biospecimens.
  • Look at biomarkers in biospecimens.


Patients having a clinically planned surgical procedure (biopsy or cytoreduction) for a suspected diagnosis of high grade glioma will be approached for participation in this study. Tumor tissue obtained from surgery will be used for histological diagnosis and clinical molecular profiling, and excess tumor tissue will be collected for potential correlative studies. A small sample of blood and CSF for research will also be collected.

Once a diagnosis of high grade glioma is confirmed, the patient will be allocated to one of the study arms. Treatment will be started approximately 7-42 days following surgery once the patient has recovered from surgery. Routine clinical evaluations will be performed prior to treatment initiation and throughout treatment as clinically indicated. Radiographic brain imaging will be performed approximately 21-42 after treatment initiation and then routinely for medical management. Tumor response will be assessed according to immunotherapy Response Assessment in Neuro-Oncology (iRANO) Working Group criteria.

Treatment may continue until the patient experiences unacceptable toxicity or clear disease progression. The determination of whether to stop treatment due to disease progression will be based on the investigator's evaluation of the patient's clinical and radiographic condition, taking into consideration the interpretation of localized inflammatory responses that can mimic radiographic features of tumor progress. Patients discontinuing treatment will have further medical management as directed by their treating physician.

As part of follow-up, if the patient undergoes a surgery, results of clinical molecular profiling will be collected, and excess resected tumor tissue will be collected if available along with blood and CSF for correlative studies. A record of any additional anti-cancer treatments and survival status will be made every three to six months.

Condition Newly Diagnosed Glioblastoma, Newly Diagnosed High Grade Glioma
Treatment Ipilimumab, bevacizumab, Temozolomide, Nivolumab, Lomustine, conformal brain radiation therapy, Metronomic Temozolomide, 5-day Temozolomide
Clinical Study IdentifierNCT03425292
SponsorJohn Wayne Cancer Institute
Last Modified on26 April 2021


Yes No Not Sure

Inclusion Criteria

Participant has the ability to understand and the willingness to provide a signed and dated informed consent form
Participant has the willingness to comply with all study procedures and availability for the duration of the study
Participant is being evaluated for a potential, or known, diagnosis of high grade glioma
Participant is a candidate for brain surgery or has undergone prior surgery and has not received any additional treatment for high grade glioma
Participant is male or female, 18 years of age
Participant has a Karnofsky Performance Status (KPS) 60%

Exclusion Criteria

Participant has received prior anti-cancer treatment for high grade glioma
Participant has a diagnosis of immunodeficiency or active autoimmune disease
Participant is receiving chronic systemic steroid therapy in dosing exceeding 8 mg daily of dexamethasone equivalent or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. Note: This is assessed after surgery, prior to starting drug treatment
Participant has received a live vaccine within 28 days prior to the first dose of study agent. Examples of live vaccines include, but are not limited to measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Gurin (BCG), typhoid vaccine, and intranasal influenza vaccines (e.g., FluMist)
Participant has a severe or uncontrolled medical disorder that would, in the investigator's opinion, impair ability to receive study intervention (i.e., uncontrolled diabetes, chronic renal disease, chronic pulmonary disease or active, uncontrolled infection, psychiatric illness/social situations that would limit compliance with study requirements)
Participant is a female of childbearing potential who is pregnant or nursing
Participant has a history of thrombotic or hemorrhagic stroke or myocardial infarction within 6 months
Participant has a history of intestinal perforations, fistula, hemorrhages, and/or hemoptysis 6 months prior to first study treatment
Participant has active gastrointestinal bleeding
Participant has uncontrolled hypertension (systolic blood pressure 160 mm Hg and/or diastolic blood pressure 90 mm Hg)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note